Overview
- Offers a comprehensive review of clinical trials in the field of Alzheimer's disease that uses the eye as a biomarker
- The first book to provide coverage clinical trials in the field of Alzheimer's disease that uses the eye as a biomarker
- Covers active studies as well as completed, withdrawn, and terminated studies
Access this book
Tax calculation will be finalised at checkout
Other ways to access
About this book
This book is a compendium of the worldwide studies of Alzheimer’s disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information.
New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment.
Alzheimer’s Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
Keywords
Table of contents (3 chapters)
Authors and Affiliations
About the author
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.
Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
Bibliographic Information
Book Title: Alzheimer's Disease and the Eye
Authors: Jeffrey N. Weiss
DOI: https://doi.org/10.1007/978-3-031-58811-2
Publisher: Springer Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
Hardcover ISBN: 978-3-031-58810-5Published: 02 July 2024
Softcover ISBN: 978-3-031-58813-6Due: 02 August 2024
eBook ISBN: 978-3-031-58811-2Published: 01 July 2024
Edition Number: 1
Number of Pages: X, 139
Topics: Ophthalmology